Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
7.6.2017

Nearly One-Third of FDA Approved Drugs Pose Safety Risks

By Brian Lynch
In The News, You Should Know, For Consumers

FDA approved drugs

The film adaptation of Richard Matheson’s novel “I am Legend” is based on a simple premise: Scientists discover what appears to be a cure for cancer, and the whole world goes to hell as a result. Sure, the treatment had proven successful on the handful of trial patients it had been tested on, so why not rush it to market? What could go wrong? Who could have known that “zombie apocalypse” was one of the side effects?

Modern medicine has undoubtedly improved the lives of countless people worldwide. But with the pharmaceutical industry raking in billions of dollars each year, big business often dictates that the next blockbuster drug must get into the hands of consumers as quickly as possible.

What could go wrong?

A lot, as it turns out.

A recent study published in JAMA shows that 32% of FDA approved drugs from 2001 through 2010 posed safety risks to consumers that were only discovered after they had been approved.

The study, which reviewed 222 products that the FDA approved, found that the administration took some sort of action to deal with safety issues that arose from nearly one-third of the products that had been cleared for sale. Of those, three drugs were removed from the market, 59 were the subject of safety communications to doctors and consumers, and 61 were issued black box warnings, the FDA’s most serious safety alert.

How is it possible that the FDA – the organization whose own mission statement charges the agency with protecting public health by assuring the safety of food and drugs – wasn’t able to catch these risks before approving the drugs?

Joseph Ross, the lead author of the study and an associate professor of medicine and public health at Yale University expounded on this problem in an interview with the Washington Post:

“We seem to have decided as a society that we want drugs reviewed faster,” said Ross.

This rush-to-the–market sentiment has been echoed by many, including current US President Donald Trump, who called the current FDA approval process “slow and burdensome.” However, the current approval process is faster than it’s ever been before thanks to the administration’s Accelerated Approval Program.  This program grants a “fast lane” for approving drugs that treat serious conditions or fill an unmet medical need. Unsurprisingly, the JAMA study also found that the treatments most likely to be flagged for safety concerns were also cleared under the Accelerated Approval Program.

Ultimately, the study concluded that there is a need for continuous monitoring of safety issues throughout the life cycle of a drug. It can be difficult to get a real-world representation of a drug’s effects based only on a small sample group tested over a short duration. Based on our experience helping clients who have been harmed by drugs and devices like hernia mesh, Essure, testosterone medication and blood thinners, the race to reach the market first is often more important than who gets trampled underfoot to many manufacturers.

Share

Comments (1)

  • 7.7.2017
    Crystal says:

    Great article Mr. Lynch! Very informative!

    Reply

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Media Appearances
  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
    • Ed Wallace
  • Practice Areas
    • Consumer Protection
    • Mass Tort Litigation
    • Business & Commercial Litigation
    • Healthcare Litigation
    • Employment Litigation
  • Cases
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • Featured Investigations
  • The Firm
    • News releases
    • Around The World
    • Our Professionals
    • Chicago
  • You Should Know
    • For Investors
    • For Businesses
    • For Consumers
  • Featured Cases
  • awards
  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP